Stereotactic body radiotherapy for T3 and T4N0M0 non-small cell lung cancer

Takahisa Eriguchi, Atsuya Takeda, Naoko Sanuki, Shuichi Nishimura, Yoshiaki Takagawa, Tatsuji Enomoto, Noriyuki Saeki, Kae Yashiro, Tomikazu Mizuno, Yousuke Aoki, Yohei Oku, Tetsuya Yokosuka, Naoyuki Shigematsu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

To evaluate the outcomes and feasibility of stereotactic body radiotherapy (SBRT) for cT3 and cT4N0M0 non-small cell lung cancer (NSCLC), 25 patients with localized primary NSCLC diagnosed as cT3 or cT4N0M0, given SBRT between May 2005 and July 2013, were analyzed. All patients had inoperable tumors. The major reasons for tumors being unresectable were insufficient respiratory function for curative resection, advanced age (>80 years old) or technically inoperable due to invasion into critical organs. The median patient age was 79 years (range; 60-86). The median follow-up duration was 25 months (range: 5-100 months). The 2-year overall survival rates for T3 and T4 were 57% and 69%, respectively. The 2-year local control rates for T3 and T4 were 91% and 68%, respectively. As for toxicities, Grade 0-1, Grade 2 and Grade 3 radiation pneumonitis occurred in 23, 1 and 1 patient, respectively. No other acute or symptomatic late toxicities were reported. Thirteen patients who had no local, mediastinal or intrapulmonary progression at one year after SBRT underwent pulmonary function testing. The median variation in pre-SBRT and post-SBRT forced expiratory volume in 1 s (FEV1) values was -0.1 (-0.8-0.8). This variation was not statistically significant (P = 0.56). Forced vital capacity (FVC), vital capacity (VC), %VC and %FEV1 also showed no significant differences. SBRT for cT3 and cT4N0M0 NSCLC was both effective and feasible. Considering the favorable survival and low morbidity rate, SBRT is a potential treatment option for cT3 and cT4N0M0 NSCLC.

Original languageEnglish
Pages (from-to)265-272
Number of pages8
JournalJournal of Radiation Research
Volume57
Issue number3
DOIs
Publication statusPublished - 2016 Jun 1

Fingerprint

Radiosurgery
Non-Small Cell Lung Carcinoma
lungs
radiation therapy
cancer
Vital Capacity
grade
Forced Expiratory Volume
toxicity
tumors
pulmonary functions
Radiation Pneumonitis
progressions
organs
Neoplasms
Survival Rate
Morbidity
Lung
Survival
radiation

Keywords

  • Inoperable
  • Non-small cell lung cancer
  • Stereotactic body radiotherapy
  • T3N0M0
  • T4N0M0
  • Unresectable

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Health, Toxicology and Mutagenesis

Cite this

Eriguchi, T., Takeda, A., Sanuki, N., Nishimura, S., Takagawa, Y., Enomoto, T., ... Shigematsu, N. (2016). Stereotactic body radiotherapy for T3 and T4N0M0 non-small cell lung cancer. Journal of Radiation Research, 57(3), 265-272. https://doi.org/10.1093/jrr/rrw023

Stereotactic body radiotherapy for T3 and T4N0M0 non-small cell lung cancer. / Eriguchi, Takahisa; Takeda, Atsuya; Sanuki, Naoko; Nishimura, Shuichi; Takagawa, Yoshiaki; Enomoto, Tatsuji; Saeki, Noriyuki; Yashiro, Kae; Mizuno, Tomikazu; Aoki, Yousuke; Oku, Yohei; Yokosuka, Tetsuya; Shigematsu, Naoyuki.

In: Journal of Radiation Research, Vol. 57, No. 3, 01.06.2016, p. 265-272.

Research output: Contribution to journalArticle

Eriguchi, T, Takeda, A, Sanuki, N, Nishimura, S, Takagawa, Y, Enomoto, T, Saeki, N, Yashiro, K, Mizuno, T, Aoki, Y, Oku, Y, Yokosuka, T & Shigematsu, N 2016, 'Stereotactic body radiotherapy for T3 and T4N0M0 non-small cell lung cancer', Journal of Radiation Research, vol. 57, no. 3, pp. 265-272. https://doi.org/10.1093/jrr/rrw023
Eriguchi T, Takeda A, Sanuki N, Nishimura S, Takagawa Y, Enomoto T et al. Stereotactic body radiotherapy for T3 and T4N0M0 non-small cell lung cancer. Journal of Radiation Research. 2016 Jun 1;57(3):265-272. https://doi.org/10.1093/jrr/rrw023
Eriguchi, Takahisa ; Takeda, Atsuya ; Sanuki, Naoko ; Nishimura, Shuichi ; Takagawa, Yoshiaki ; Enomoto, Tatsuji ; Saeki, Noriyuki ; Yashiro, Kae ; Mizuno, Tomikazu ; Aoki, Yousuke ; Oku, Yohei ; Yokosuka, Tetsuya ; Shigematsu, Naoyuki. / Stereotactic body radiotherapy for T3 and T4N0M0 non-small cell lung cancer. In: Journal of Radiation Research. 2016 ; Vol. 57, No. 3. pp. 265-272.
@article{1d61da76b92b40e89566e5ca52c8f0f6,
title = "Stereotactic body radiotherapy for T3 and T4N0M0 non-small cell lung cancer",
abstract = "To evaluate the outcomes and feasibility of stereotactic body radiotherapy (SBRT) for cT3 and cT4N0M0 non-small cell lung cancer (NSCLC), 25 patients with localized primary NSCLC diagnosed as cT3 or cT4N0M0, given SBRT between May 2005 and July 2013, were analyzed. All patients had inoperable tumors. The major reasons for tumors being unresectable were insufficient respiratory function for curative resection, advanced age (>80 years old) or technically inoperable due to invasion into critical organs. The median patient age was 79 years (range; 60-86). The median follow-up duration was 25 months (range: 5-100 months). The 2-year overall survival rates for T3 and T4 were 57{\%} and 69{\%}, respectively. The 2-year local control rates for T3 and T4 were 91{\%} and 68{\%}, respectively. As for toxicities, Grade 0-1, Grade 2 and Grade 3 radiation pneumonitis occurred in 23, 1 and 1 patient, respectively. No other acute or symptomatic late toxicities were reported. Thirteen patients who had no local, mediastinal or intrapulmonary progression at one year after SBRT underwent pulmonary function testing. The median variation in pre-SBRT and post-SBRT forced expiratory volume in 1 s (FEV1) values was -0.1 (-0.8-0.8). This variation was not statistically significant (P = 0.56). Forced vital capacity (FVC), vital capacity (VC), {\%}VC and {\%}FEV1 also showed no significant differences. SBRT for cT3 and cT4N0M0 NSCLC was both effective and feasible. Considering the favorable survival and low morbidity rate, SBRT is a potential treatment option for cT3 and cT4N0M0 NSCLC.",
keywords = "Inoperable, Non-small cell lung cancer, Stereotactic body radiotherapy, T3N0M0, T4N0M0, Unresectable",
author = "Takahisa Eriguchi and Atsuya Takeda and Naoko Sanuki and Shuichi Nishimura and Yoshiaki Takagawa and Tatsuji Enomoto and Noriyuki Saeki and Kae Yashiro and Tomikazu Mizuno and Yousuke Aoki and Yohei Oku and Tetsuya Yokosuka and Naoyuki Shigematsu",
year = "2016",
month = "6",
day = "1",
doi = "10.1093/jrr/rrw023",
language = "English",
volume = "57",
pages = "265--272",
journal = "Journal of Radiation Research",
issn = "0449-3060",
publisher = "Japan Radiation Research Society",
number = "3",

}

TY - JOUR

T1 - Stereotactic body radiotherapy for T3 and T4N0M0 non-small cell lung cancer

AU - Eriguchi, Takahisa

AU - Takeda, Atsuya

AU - Sanuki, Naoko

AU - Nishimura, Shuichi

AU - Takagawa, Yoshiaki

AU - Enomoto, Tatsuji

AU - Saeki, Noriyuki

AU - Yashiro, Kae

AU - Mizuno, Tomikazu

AU - Aoki, Yousuke

AU - Oku, Yohei

AU - Yokosuka, Tetsuya

AU - Shigematsu, Naoyuki

PY - 2016/6/1

Y1 - 2016/6/1

N2 - To evaluate the outcomes and feasibility of stereotactic body radiotherapy (SBRT) for cT3 and cT4N0M0 non-small cell lung cancer (NSCLC), 25 patients with localized primary NSCLC diagnosed as cT3 or cT4N0M0, given SBRT between May 2005 and July 2013, were analyzed. All patients had inoperable tumors. The major reasons for tumors being unresectable were insufficient respiratory function for curative resection, advanced age (>80 years old) or technically inoperable due to invasion into critical organs. The median patient age was 79 years (range; 60-86). The median follow-up duration was 25 months (range: 5-100 months). The 2-year overall survival rates for T3 and T4 were 57% and 69%, respectively. The 2-year local control rates for T3 and T4 were 91% and 68%, respectively. As for toxicities, Grade 0-1, Grade 2 and Grade 3 radiation pneumonitis occurred in 23, 1 and 1 patient, respectively. No other acute or symptomatic late toxicities were reported. Thirteen patients who had no local, mediastinal or intrapulmonary progression at one year after SBRT underwent pulmonary function testing. The median variation in pre-SBRT and post-SBRT forced expiratory volume in 1 s (FEV1) values was -0.1 (-0.8-0.8). This variation was not statistically significant (P = 0.56). Forced vital capacity (FVC), vital capacity (VC), %VC and %FEV1 also showed no significant differences. SBRT for cT3 and cT4N0M0 NSCLC was both effective and feasible. Considering the favorable survival and low morbidity rate, SBRT is a potential treatment option for cT3 and cT4N0M0 NSCLC.

AB - To evaluate the outcomes and feasibility of stereotactic body radiotherapy (SBRT) for cT3 and cT4N0M0 non-small cell lung cancer (NSCLC), 25 patients with localized primary NSCLC diagnosed as cT3 or cT4N0M0, given SBRT between May 2005 and July 2013, were analyzed. All patients had inoperable tumors. The major reasons for tumors being unresectable were insufficient respiratory function for curative resection, advanced age (>80 years old) or technically inoperable due to invasion into critical organs. The median patient age was 79 years (range; 60-86). The median follow-up duration was 25 months (range: 5-100 months). The 2-year overall survival rates for T3 and T4 were 57% and 69%, respectively. The 2-year local control rates for T3 and T4 were 91% and 68%, respectively. As for toxicities, Grade 0-1, Grade 2 and Grade 3 radiation pneumonitis occurred in 23, 1 and 1 patient, respectively. No other acute or symptomatic late toxicities were reported. Thirteen patients who had no local, mediastinal or intrapulmonary progression at one year after SBRT underwent pulmonary function testing. The median variation in pre-SBRT and post-SBRT forced expiratory volume in 1 s (FEV1) values was -0.1 (-0.8-0.8). This variation was not statistically significant (P = 0.56). Forced vital capacity (FVC), vital capacity (VC), %VC and %FEV1 also showed no significant differences. SBRT for cT3 and cT4N0M0 NSCLC was both effective and feasible. Considering the favorable survival and low morbidity rate, SBRT is a potential treatment option for cT3 and cT4N0M0 NSCLC.

KW - Inoperable

KW - Non-small cell lung cancer

KW - Stereotactic body radiotherapy

KW - T3N0M0

KW - T4N0M0

KW - Unresectable

UR - http://www.scopus.com/inward/record.url?scp=84978955234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978955234&partnerID=8YFLogxK

U2 - 10.1093/jrr/rrw023

DO - 10.1093/jrr/rrw023

M3 - Article

C2 - 26983978

AN - SCOPUS:84978955234

VL - 57

SP - 265

EP - 272

JO - Journal of Radiation Research

JF - Journal of Radiation Research

SN - 0449-3060

IS - 3

ER -